HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ANALYSIS OF IDARUBICIN AND FLUORESCENT METABOLITES IN BIOLOGICAL-FLUIDS

被引:24
作者
CAMAGGI, CM [1 ]
CARISI, P [1 ]
STROCCHI, E [1 ]
PANNUTI, F [1 ]
机构
[1] OSPED M MALPIGHI,DIV ONCOL,BOLOGNA,ITALY
关键词
IDARUBICIN; METABOLITES;
D O I
10.1007/BF00686300
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A specific, sensitive, and reliable high-performance liquid chromatographic (HPLC) method for the determination of idarubicin (IDA) and its known fluorescent metabolites idarubicinol (IDAol) and 4-demethoxy-daunomycinone (AG1) in biological fluids (human plasma and urine) was developed and tested. Plasma samples were solid-phase-extracted (C18 bonded silica cartridges). Complete separation of unchanged drugs and metabolites was achieved on a Cyanopropyl chromatographic column (25 cm x 4.6 mm inside diameter; particle size, 5-mu-m) using fluorescence detection (excitation wavelength, 470 nm; emission wavelength, 580 nm). Sensitivity was better than 0.2 ng/ml for all analytes; rates of recovery of unchanged drug and metabolites were better than 84.5% (IDA), 80.3% (IDAol), and 83.9% (AG1). The interassay coefficient of variation was 6.5% for IDA, 5.8% for IDAol, and 9.8% for AG1. Mean intra-assay precision was 4.6% for IDA, 5.9% for IDAol, and 5.0% for AG1 at sample concentrations of above 1 ng/ml and 12.1% for IDA, 10.8% for IDAol, and 14.1% for AG1 at sample concentrations of below 1 ng/ml.
引用
收藏
页码:303 / 306
页数:4
相关论文
共 10 条
[1]  
BERMAN E, 1983, CANCER RES, V43, P6096
[2]  
CASAZZA AM, 1983, P AM ASSOC CANC RES, V24, P251
[3]  
CUMMINGS J, 1987, CANCER CHEMOTH PHARM, V19, P296
[4]  
DAGHESTANI AN, 1985, CANCER RES, V45, P1408
[5]   IDARUBICIN (4-DEMETHOXYDAUNORUBICIN) - A PRELIMINARY OVERVIEW OF PRECLINICAL AND CLINICAL-STUDIES [J].
GANZINA, F ;
PACCIARINI, MA ;
DIPIETRO, N .
INVESTIGATIONAL NEW DRUGS, 1986, 4 (01) :85-105
[6]   PHARMACOKINETICS OF IDARUBICIN (4-DEMETHOXYDAUNORUBICIN IMI-30 NSC 256439) FOLLOWING INTRAVENOUS AND ORAL-ADMINISTRATION IN PATIENTS WITH ADVANCED CANCER [J].
GILLIES, HC ;
HERRIOTT, D ;
LIANG, R ;
OHASHI, K ;
ROGERS, HJ ;
HARPER, PG .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 23 (03) :303-310
[7]   CLINICAL-PHARMACOLOGY OF 4-DEMETHOXYDAUNORUBICIN (DMDR) [J].
LU, K ;
SAVARAJ, N ;
KAVANAGH, J ;
FEUN, LG ;
BURGESS, M ;
BODEY, GP ;
LOO, TL .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1986, 17 (02) :143-148
[8]  
MORO E, 1983, J CHROMATOGR, V247, P281
[9]   LOW-DOSE ORAL-ADMINISTRATION OF 4-DEMETHOXY-DAUNORUBICIN (IDARUBICIN) IN ADVANCED CANCER-PATIENTS - A PHARMACOKINETIC STUDY [J].
PANNUTI, F ;
CAMAGGI, CM ;
STROCCHI, E ;
COMPARSI, R ;
ANGELELLI, B ;
PACCIARINI, MA .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1986, 16 (03) :295-299
[10]  
SMITH DB, 1987, CANCER CHEMOTH PHARM, V19, P138